Wall Street brokerages expect Integra Lifesciences Holdings Corp (NASDAQ:IART) to announce $361.96 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Integra Lifesciences’ earnings, with the lowest sales estimate coming in at $359.03 million and the highest estimate coming in at $370.70 million. Integra Lifesciences posted sales of $357.08 million during the same quarter last year, which suggests a positive year over year growth rate of 1.4%. The firm is scheduled to announce its next earnings results before the market opens on Wednesday, April 24th.
On average, analysts expect that Integra Lifesciences will report full year sales of $1.52 billion for the current financial year. For the next year, analysts expect that the firm will report sales of $1.60 billion, with estimates ranging from $1.59 billion to $1.61 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Thursday, February 21st. The life sciences company reported $0.65 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.03. Integra Lifesciences had a net margin of 4.13% and a return on equity of 16.02%. The business had revenue of $383.30 million during the quarter, compared to analysts’ expectations of $382.33 million. During the same period in the prior year, the company earned $0.64 earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis.
In related news, Director Rhonda Germany Ballintyn bought 1,933 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was bought at an average cost of $56.08 per share, with a total value of $108,402.64. Following the completion of the purchase, the director now owns 3,665 shares of the company’s stock, valued at approximately $205,533.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lisa Evoli sold 1,291 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $55.90, for a total transaction of $72,166.90. Following the transaction, the insider now directly owns 4,968 shares of the company’s stock, valued at $277,711.20. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Research Global Investors lifted its position in Integra Lifesciences by 4.3% during the third quarter. Capital Research Global Investors now owns 10,186,218 shares of the life sciences company’s stock valued at $670,966,000 after purchasing an additional 423,324 shares during the last quarter. BlackRock Inc. lifted its position in Integra Lifesciences by 3.2% during the fourth quarter. BlackRock Inc. now owns 6,730,304 shares of the life sciences company’s stock valued at $303,536,000 after purchasing an additional 210,960 shares during the last quarter. Clearbridge Investments LLC lifted its position in Integra Lifesciences by 7.9% during the third quarter. Clearbridge Investments LLC now owns 1,810,641 shares of the life sciences company’s stock valued at $119,267,000 after purchasing an additional 132,805 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in Integra Lifesciences by 4,410.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 1,226,245 shares during the last quarter. Finally, Capital World Investors lifted its position in Integra Lifesciences by 438.9% during the third quarter. Capital World Investors now owns 1,137,015 shares of the life sciences company’s stock valued at $74,895,000 after purchasing an additional 926,015 shares during the last quarter. 83.89% of the stock is owned by institutional investors.
IART stock traded down $0.62 during midday trading on Thursday, reaching $54.00. 192,900 shares of the company’s stock traded hands, compared to its average volume of 473,403. Integra Lifesciences has a 52-week low of $42.14 and a 52-week high of $67.50. The stock has a market cap of $4.62 billion, a P/E ratio of 22.31, a P/E/G ratio of 1.59 and a beta of 0.96. The company has a current ratio of 2.95, a quick ratio of 1.88 and a debt-to-equity ratio of 0.97.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.